CATX news

The company reported robust tumor responses and durable disease control in a study of [212Pb]VMT-alpha-NET for neuroendocrine tumors, aiming to begin Phase 3 trials in 2027.

Perspective Therapeutics announced FDA Fast Track Designation for PSV359 treating rare fibroblast activation protein-positive solitary fibrous tumors.

Perspective Therapeutics and Merck are partnering to evaluate [212Pb]PSV359 combined with Keytruda in solid tumors, potentially reshaping the tumor microenvironment for improved cancer outcomes.

Perspective Therapeutics, Inc. (NYSE American: CATX) announced 2Q 2026 results, advancing programs like VMT-α-NET toward a Phase 3 study while reporting over $237 million in cash to fund operations into late 2027.

Perspective Therapeutics presented clinical data on three wholly-owned radiopharmaceutical candidates targeting oncology indications including neuroendocrine tumors, melanoma, and solid tumors. The company's next-generation alpha-emitter platform and regional manufacturing strategy position it to ex…

Perspective Therapeutics announced it will present updates on three radiopharmaceutical programs at the 2026 ASCO Annual Meeting, including positive interim data from its [212Pb]VMT01 melanoma study showing 29% response rate and well-tolerated safety profile across all programs. The updates demonstr…